Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab in Breast Milk of Lactating Women With IBD
NCT06346288Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2024
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 4 trial of risankizumab in inflammatory bowel disease (IBD), sponsored by AbbVie Inc.. Started Apr 2024; status: completed.
02
Drugs
risankizumab
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT06346288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06346288.